Biomimetic hematoma + rhBMP-2 and tirzepatide achieve complete union in complex periprosthetic fracture nonunion.
Background
Periprosthetic fracture nonunion presents a significant challenge, particularly in elderly patients with multiple comorbidities, where conventional treatments often fail. These complex cases are characterized by poor bone quality, compromised vascularity, and systemic factors that impede healing. Current surgical interventions for nonunion frequently struggle to achieve robust bone regeneration, leading to prolonged recovery and reduced functional outcomes. The need for innovative strategies that can enhance local bone healing while addressing systemic metabolic issues is critical. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is known for its osteoinductive properties, but its delivery and efficacy can be optimized. This case explores a novel biomimetic approach to bridge this therapeutic gap.
Study Design
This case report details the management of an 80-year-old woman with a history of revision total knee arthroplasty, presenting with a severe periprosthetic tibial nonunion and varus deformity. She underwent dual-plate fixation combined with a novel biomimetic hematoma (BH) scaffold. The BH scaffold was designed to deliver low-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) directly to the nonunion site. Post-surgery, tirzepatide was initiated as an additional systemic intervention. The primary outcomes assessed were radiographic evidence of bone union and functional recovery, alongside changes in body weight over a 1-year follow-up period.
Results
The combined therapeutic approach yielded remarkable results in this challenging case. Radiographs confirmed complete union at 4 months post-surgery, demonstrating effective bone regeneration at the previously non-healing site. The patient's functional status significantly improved over the follow-up period; she progressed from wheelchair dependence to achieving full weight bearing with walker assistance at 1 year. > Notably, the patient also experienced a substantial 75-pound weight loss following the initiation of tirzepatide, which likely contributed to her overall functional recovery and reduced mechanical stress on the healing joint. This outcome highlights the potential synergy between localized osteoinductive therapy and systemic metabolic management in promoting complex fracture healing. The successful union and functional restoration underscore the efficacy of the BH + rhBMP-2 scaffold in a high-risk patient.
Key Findings
- Biomimetic hematoma (BH) with low-dose rhBMP-2 achieved complete union of a periprosthetic tibial nonunion at 4 months.
- Patient progressed from wheelchair dependence to full weight bearing with walker assistance at 1 year.
- Initiation of tirzepatide led to a significant 75-pound weight loss.
- Combined local osteoinductive therapy and systemic metabolic management enabled successful healing in a medically complex patient.
Why It Matters
This case report suggests a powerful new strategy for tackling complex periprosthetic fracture nonunions, especially in medically fragile patients. The integration of a biomimetic hematoma scaffold delivering rhBMP-2 offers a localized, potent osteoinductive stimulus. Crucially, the concurrent initiation of tirzepatide points to the potential benefits of addressing systemic metabolic factors like obesity, which can hinder bone healing and functional recovery. For clinicians, this highlights the value of a multi-modal approach, combining advanced local regenerative techniques with systemic metabolic optimization. While a single case, it opens avenues for exploring how tirzepatide's metabolic effects (e.g., weight loss, improved insulin sensitivity) might indirectly support orthopedic healing, potentially reducing mechanical load and enhancing tissue repair processes. This could inform future protocols for patients with comorbidities.